Datasheet

FLI1 Antibody
CATALOG NUMBER: 7449

Availability: In stock

$0.00
Product Price Options

* Required Fields

$0.00
Specifications
Properties
Additional Info
Background

Specifications

SPECIES REACTIVITY:Human, Mouse, Rat
HOMOLOGY:Predicted species reactivity based on immunogen sequence: Bovine: (100%)
TESTED APPLICATIONS:ELISA, IF, WB
APPLICATIONS:FLI1 antibody can be used for detection of FLI1 by Western blot at 0.5 - 1 μg/ml.
USER NOTE:Optimal dilutions for each application to be determined by the researcher.
POSITIVE CONTROL:1) Cat. No. 1205 - Jurkat Cell Lysate
 2) Cat. No. 17-001 - HeLa Cell Slide
PREDICTED MOLECULAR WEIGHT:Predicted: 50 kDa

Observed: 52kDa
SPECIFICITY:FLI1 antibody is human, mouse and rat reactive. At least four isoforms of FLI1 are known to exist; this antibody will detect all four.
IMMUNOGEN:FLI1 antibody was raised against a 17 amino acid peptide near the carboxy terminus of human FLI1.

The immunogen is located within the last 50 amino acids of FLI1 .
HOST SPECIES:Rabbit

Properties

PURIFICATION:FLI1 Antibody is affinity chromatography purified via peptide column.
PHYSICAL STATE:Liquid
BUFFER:FLI1 Antibody is supplied in PBS containing 0.02% sodium azide.
CONCENTRATION:1 mg/mL
STORAGE CONDITIONS:FLI1 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year.
CLONALITY:Polyclonal
ISOTYPE:IgG
CONJUGATE:Unconjugated

Additional Info

ALTERNATE NAMES:FLI1 Antibody: EWSR2, SIC-1, BDPLT21
ACCESSION NO.:NP_002008
PROTEIN GI NO.:7110593
OFFICIAL SYMBOL:FLI1
GENE ID:2313

Background

BACKGROUND:The Friend leukemia virus integration 1 (FLI1) protein is a transcription factor containing an ETS DNA-binding domain and is highly expressed in hematopoietic cell lineages and vascular endothelial cells (1). FLI1 plays important roles in megakaryocytic differentiation (2) and vascular homeostasis (3). The FLI1 gene can undergo a t(11;22)(q24;q12) translocation with the Ewing sarcoma gene on chromosome 22, which results in a fusion gene that is present in the majority of Ewing sarcoma cases. (4). Abnormal expression of FLI1 can be used as an adverse prognostic indicator for acute myeloid leukemia (5).
REFERENCES: 1) Hollenhorst PC, Jones DA, and Graves BJ. Expression profiles frame the promoter specificity dilemma of the ETS family of transcription factors. Nuc. Acids Res. 2004; 32:5693-702.
2) Spyropoulos DD, Pharr PN, Lavenburg KR, et al. Hemorrhage, impaired hematopoiesis, and lethality in mouse embryos carrying a targeted disruption of the Fli1 transcription factor. Mol. Cell Biol. 2000; 20:5643-52.
3) Asano Y, Stawski L, Hant F, et al. Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am. J. Pathol. 2010; 176:1983-98.
4) May WA, Gishizky ML, Lessnick SL, et al. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc. Natl. Acad. Sci. USA 1993; 90:5752-6. 5. Kornblau SM, Qiu YH, Zhang N, et al. Abnormal expression of FLI1 protein is an adverse prognostic factor in acute myeloid leukemia. Blood 2011; 118:5604-12.

For Research Use Only